People_

Professor Michael Boyer

Clinical Professor
Medicine, Central Clinical School

Phone

+61 2 8514 0140

Fax

+61 2 9383 1014

michael.boyer@sydney.edu.au

Websites

Related website

Biographical details

Following his specialty training in medical oncology at Royal Prince Alfred and Westmead Hospitals, Professor Boyer was a Research Fellow and Clinical Fellow at the Ontario Cancer Institute and Princess Margaret Hospital in Toronto, Canada, where he completed his PhD on cell biology. He was on the senior staff of the Sydney Cancer Centre and Royal Prince Alfred Hospital from 1993 to 2013, at which time he joined the newly opened Chris O’Brien Lifehouse. In addition to his clinical roles, he has held senior administrative positions during that time including Head of Department of Medical Oncology at Royal Prince Alfred Hospital, Director of the Sydney Cancer Centre, and Area Director of Cancer Services for the Sydney South West Area Health Service. His clinical interests are in the management of thoracic malignancies and head and neck cancers, His research training includes a laboratory PhD at the University of Toronto between 1990 and 1993. His more recent major research interest is in clinical trials of new agents in the management of lung cancer and mesothelioma. He is the author of over 145 publications, has given numerous national and international presentations, both invited and selected from abstract submission, and is actively involved in the lung cancer community. He chaired the scientific advisory committee of the Australasian Lung Cancer Trials Group between 2004 and 2011, and was the conference Co-President for the 15^th World Conference on Lung Cancer held in Sydney in 2013. He is currently a member of the Board of Directors of the International Association for the Study of Lung Cancer.

Awards and honours

Member of the Order of Australia 2010

Themes

Cancer

Keywords

Head and neck cancer, Lung cancer

Approaches

Clinical Trials, Epidemiology

Clinical speciality

Oncology

Current research students

Project title	Research student
Impact of intra-infusion aerobic exercise on tumour vascularity in patients with cancer	Catherine SEET-LEE

Publications

By Type

Expand all

Book Chapters

Boyer, M. (2003). Pleural and pericardial effusions. In Fisch, Bruera (Eds.), Handbook of Advanced Cancer Care, (pp. 481-487). UK: Cambridge University Press.

Journals

Brown, B., Galpin, K., Simes, R., Boyer, M., Brown, C., Chin, V., Young, J. (2024). Development of clinically meaningful quality indicators for contemporary lung cancer care, and piloting and evaluation in a retrospective cohort; experiences of the Embedding Research (and Evidence) in Cancer Healthcare (EnRICH) Program. BMJ Open, 14(2), e074399. [More Information]
Brown, L., Khou, V., Brown, C., Alexander, M., Jayamanne, D., Wei, J., Gray, L., Chan, W., Smith, S., Harden, S., Mersiades, T., Itchins, M., Pavlakis, N., Clarke, S., Boyer, M., Nagrial, A., Hau, E., Esteves Domingues Pires da Silva, I., Kao, S., Kong, B., et al (2024). First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study. Frontiers in Oncology, 14. [More Information]
Boyer, M., Hui, R., Urban, D., Clingan, P., Su, W., Devaux, C., Gadgeel, S., Garassino, M., Leopold, L., Daniel, J., et al (2024). Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer, 23(Suppl 1). [More Information]
Dowlati, A., Yoshida, T., Bouchaab, H., Borghaei, H., Felip, E., Jost, P., Gadgeel, S., Chen, X., Yu, Y., Martinez, P., Boyer, M., et al (2024). Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. Journal of Clinical Oncology, , 10.1200/JCO.24.00553. [More Information]
Smith, S., Kao, S., Boyer, M., Franco, M., Moore, M. (2024). Treatment selection and real-world analysis of immunotherapy with or without chemotherapy in PD-L1-high metastatic non-small cell lung cancer. Internal Medicine Journal. [More Information]
Brown, B., Galpin, K., Simes, R., Boyer, M., Chin, V., Young, J. (2023). Clinicians' Evaluation of Lung Cancer Clinical Quality Indicators and Comparative Performance Data in Practice. European Journal of Cancer Care, 2023, 6636704. [More Information]
Nindra, U., Shahnam, A., Stevens, S., Pal, A., Nagrial, A., Lee, J., Yip, P., Adam, T., Boyer, M., Kao, S., et al (2023). Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia-Pacific Journal of Clinical Oncology. [More Information]
Nindra, U., Shahnam, A., Stevens, S., Pal, A., Nagrial, A., Lee, J., Yip, P., Adam, T., Boyer, M., Kao, S., et al (2022). Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumab. Thoracic Cancer, 13(21), 3058-3062. [More Information]
Carroll, R., Boyer, M., Gebski, V., Hockley, B., Johnston, J., Kireta, S., Tan, H., Taylor, A., Wyburn, K., Zalcberg, J. (2022). Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study. The Lancet Oncology, 23(8), 1078-1086. [More Information]
Lo, J., Ballurkar, K., Fox, S., Tynan, K., Luu, N., Boyer, M., Murali-Ganesh, R. (2021). A digital coaching intervention for cancer survivors with job loss: Retrospective study. JMIR Cancer, 7(4), e31966. [More Information]
Davis, A., Cooper, W., Boyer, M., Lee, J., Pavlakis, N., Kao, S. (2021). Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy, 13(11), 941-952. [More Information]
Davis, A., Kao, S., Clarke, S., Boyer, M., Pavlakis, N. (2021). Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opinion on Emerging Drugs, 26(2), 179-192. [More Information]
Satgunaseelan, L., Porazinski, S., Strbenac, D., Istadi, A., Willet, C., Chew, T., Sadsad, R., Palme, C., Lee, J., Boyer, M., Yang, J., Clark, J., Gupta, R., et al (2021). Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy. Frontiers in Oncology, 11, 750852. [More Information]
O Parsonson, A., Grimison, P., Boyer, M., Horvath, L., Mahon, K., Beith, J., Kao, S., Hui, M., Sutherland, S., Kumar, S., Heller, G., McNeil, C. (2021). Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemic. Journal of Telemedicine and Telecare. [More Information]
Liu, J., Itchins, M., Nagrial, A., Cooper, W., De Silva, M., Barnet, M., Varikatt, W., Sivasubramaniam, V., Davis, A., Gill, A., Blinman, P., Lee, K., Hui, R., Pavlakis, N., Clarke, S., Boyer, M., Kao, S., et al (2021). Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 155, 28-33. [More Information]
Thomas, V., Seet-Lee, C., Marthick, M., Cheema, B., Boyer, M., Edwards, K. (2020). Aerobic exercise during chemotherapy infusion for cancer treatment: a novel randomised crossover safety and feasibility trial. Supportive Care in Cancer, 28(2), 625-632. [More Information]
Itchins, M., Lau, B., Hudson, A., Westman, H., Xia, C., Hayes, S., Howell, V., Rodriguez, M., Cooper, W., Wei, G., Buckland, M., Li, B., Gill, A., Clarke, S., Pavlakis, N., et al (2020). ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. The Oncologist, 25(8), 641-649. [More Information]
Findlay, M., Rankin, N., Shaw, T., White, K., Boyer, M., Milross, C., Lourenço, R., Brown, C., Collett, G., Beale, P., et al (2020). Best evidence to best practice: implementing an innovative model of nutrition care for patients with head and neck cancer improves outcomes. Nutrients, 12(5), 1465. [More Information]
Liu, J., Wong, K., Patanjali, N., Boyer, M., Kao, S. (2020). Case of post-progression prolongation of survival after cessation of pembrolizumab in advanced non-small-cell lung cancer. Internal Medicine Journal, 50(6), 771-773. [More Information]
Lau, B., Boyer, M., Lee, J., Kao, S. (2020). Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. Clinical Lung Cancer, 21(4), 378-3.83E+03. [More Information]
Davis, A., Boyer, M., Lee, J., Kao, S. (2020). COVID-19: the use of immunotherapy in metastatic lung cancer. Immunotherapy, 12(8), 545-548. [More Information]
Garassino, M., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., Domine, M., Hochmair, M., Powell, S., Cheng, S., Bischoff, H., Hui, R., et al (2020). Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 21(3), 387-397. [More Information]
Razak, A., Cleary, J., Moreno, V., Boyer, M., Calvo Aller, E., Edenfield, W., Tie, J., Harvey, R., Rutten, A., Shah, M., et al (2020). Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 8(2), e001006. [More Information]
Gadgeel, S., Rodriguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Domine, M., Hui, R., Hochmair, M., Clingan, P., Powell, S., et al (2020). Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38(14), 1505-1517. [More Information]
Schuler, M., Tan, E., O’Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J., Lee, K., Lu, S., et al (2019). First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology, 145(6), 1569-1579. [More Information]
Peters, S., Dafni, U., Boyer, M., de Ruysscher, D., Faivre-Finn, C., Felip, E., Garrido, P., Girard, N., Guckenberger, M., Haanen, J., et al (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 30(2), 161-165. [More Information]
Planchard, D., Boyer, M., Lee, J., Dechaphunkul, A., Cheema, P., Takahashi, T., Gray, J., Tiseo, M., Ramalingam, S., Todd, A., et al (2019). Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 25(7), 2058-2063. [More Information]
Prasanna, T., Arasaratnam, M., Boyer, M., McNeil, C., Barnet, M., Asher, R., Hui, R., Nagrial, A., Kao, S. (2019). Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer. Immunotherapy, 11, 657-665. [More Information]
Park, K., Bennouna, J., Boyer, M., Hida, T., Hirsh, V., Kato, T., Lu, S., Mok, T., Nakagawa, K., O’Byrne, K., et al (2019). Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 132, 126-131. [More Information]
Wu, Y., Sequist, L., Tan, E., Geater, S., Orlov, S., Zhang, L., Lee, K., Tsai, C., Kato, T., Boyer, M., et al (2018). Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer, 19(4), e465-e479. [More Information]
Ahmadzada, T., Kao, S., Reid, G., Boyer, M., Mahar, A., Cooper, W. (2018). An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 7(6), E153. [More Information]
Prasanna, T., Beith, J., Kao, S., Boyer, M., McNeil, C. (2018). Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 14(3), 125-133. [More Information]
Barnet, M., Cooper, W., Boyer, M., Kao, S. (2018). Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. Journal of Clinical Medicine, 7(6), 151. [More Information]
Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M., Powell, S., Hui, R., Boyer, M., et al (2018). Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378(22), 2078-2092. [More Information]
Gerber, D., Horn, L., Boyer, M., Sanborn, R., Natale, R., Palmero, R., Bidoli, P., Bondarenko, I., Germonpre, P., et al (2018). Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Annals of Oncology, 29(7), 1548-1553. [More Information]
Bui, K., Cooper, W., Kao, S., Boyer, M. (2018). Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 7(8), 1-18. [More Information]
Barnet, M., Blinman, P., Cooper, W., Boyer, M., Kao, S., Goodnow, C. (2018). Understanding Immune Tolerance of Cancer: Re-Purposing Insights from Fetal Allografts and Microbes. BioEssays, 40(8), 1-6. [More Information]
Paz-Ares, L., Tan, E., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J., Mok, T., Lee, K., Lu, S., et al (2017). Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology, 28(2), 270-277. [More Information]
Barnet, M., O'Toole, S., Horvath, L., Selinger, C., Yu, B., Ng, C., Boyer, M., Cooper, W., Kao, S. (2017). EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 12(3), 585-590. [More Information]
Dhillon, H., Bell, M., van der Ploeg, H., Turner, J., Kabourakis, M., Spencer, L., Lewis, C., Hui, R., Blinman, P., Clarke, S., Boyer, M., Vardy, J. (2017). Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: A randomized controlled trial. Annals of Oncology, 28(8), 1889-1897. [More Information]
Kunchok, A., Barnes, D., Boyer, M., Halmagyi, G. (2017). Paraneoplastic cerebellar ataxia with central hypoventilation. Neurology: Neuroimmunology and Neuroinflammation, 4(1), 1-2. [More Information]
Lau, B., Kumar, S., Yan, T., Burn, J., Kennedy, C., McLean, J., Boyer, M., McCaughan, B., Kao, S. (2017). Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes. Lung Cancer, 111, 75-78. [More Information]
Roper, E., Lum, T., Palme, C., Ashford, B., Ch'ng, S., Ranson, M., Boyer, M., Clark, J., Gupta, R. (2017). PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology, 49(5), 499-505. [More Information]
van Zandwijk, N., Pavlakis, N., Kao, S., Linton, A., Boyer, M., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M., Bailey, D., Cooper, W., Kritharides, L., Reid, G., et al (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. The Lancet Oncology, 18(10), 1386-1396. [More Information]
Khoo, T., Yu, B., Smith, J., Clarke, A., Luk, P., Selinger, C., Mahon, K., Kraitsek, S., Palme, C., Boyer, M., O'Toole, S., Clark, J., Gupta, R., et al (2017). Somatic mutations in salivary duct carcinoma and potential therapeutic targets. Oncotarget, 8(44), 75893-75903. [More Information]
Kao, S., Cheng, Y., Williams, M., Kirschner, M., Madore, J., Lum, T., Sarun, K., Linton, A., McCaughan, B., Klebe, S., van Zandwijk, N., Scolyer, R., Boyer, M., Cooper, W., Reid, G. (2017). Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. [More Information]
Park, K., Tan, E., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J., Lee, K., Lu, S., et al (2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology, 17(5), 577-589. [More Information]
Reid, G., Kao, S., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., van Zandwijk, N. (2016). Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics, 8(8), 1079-1085. [More Information]
Ramalingam, S., O'Byrne, K., Boyer, M., Mok, T., Janne, P., Zhang, H., Liang, J., Taylor, I., Sbar, E., Paz-Ares, L. (2016). Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of Oncology, 27(3), 423-429. [More Information]
Kao, S., Boyer, M. (2016). Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 34(27), 3233-3234. [More Information]
Lomax, A., Beith, J., Bhadri, V., Boyer, M., Grimison, P., Horvath, L., Kao, S., Tattersall, M., Thomas, D., McNeil, C. (2016). Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse. Internal Medicine Journal, 46(12), 1392-1398. [More Information]
Satgunaseelan, L., Gupta, R., Madore, J., Chia, N., Lum, T., Palme, C., Boyer, M., Scolyer, R., Clark, J. (2016). Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 48(6), 574-580. [More Information]
Luk, P., Weston, J., Yu, B., Selinger, C., Ekmejian, R., Eviston, T., Lum, T., Gao, K., Boyer, M., O'Toole, S., Clark, J., Gupta, R. (2016). Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head and Neck, 38(Suppl 1), e1838-e1847. [More Information]
Davidson, A., Veillard, A., Tognela, A., Chan, M., Huighes, B., Boyer, M., Briscoe, K., Begbie, S., Abdi, E., Crombie, C., Chinchen, S., Espinoza, D., Coskinas, X., Pavlakis, N., Stockler, M., et al (2015). A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. Annals of Oncology, 26(11), 2280-2286. [More Information]
Kao, S., Fulham, M., Wong, K., Cooper, W., Brahmbhatt, H., MacDiarmid, J., Pattison, S., Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N., Clarke, S., Boyer, M., Reid, G., van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine, 191(12), 1467-1469. [More Information]
Yang, J., Wu, Y., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C., O'Byrne, K., Feng, J., Boyer, M., et al (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology, 16(2), 141-151. [More Information]
Mahon, K., Lin, H., Castillo, L., Lee, B., Lee-Ng, K., Chatfield, M., Chiam, K., Breit, S., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Horvath, L., et al (2015). Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. British Journal of Cancer, 112(8), 1340-1348. [More Information]
Brunner, M., Gore, S., Read, R., Alexander, A., Mehta, A., Elliott, M., Milross, C., Boyer, M., Clark, J. (2015). Head and neck multidisciplinary team meetings: Effect on patient management. Head and Neck, 37(7), 1046-1050. [More Information]
Cooper, W., Tran, T., Vilain, R., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P., Yu, B., O'Toole, S., McCaughan, B., Horvath, L., Kao, S., Boyer, M., Scolyer, R., et al (2015). PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2), 181-188. [More Information]
Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
Ramalingam, S., Jänne, P., Mok, T., O'Byrne, K., Boyer, M., von Pawel, J., Pluzanski, A., Shtivelband, M., Iglesias Docampo, L., Bennouna, J., et al (2014). Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. The Lancet Oncology, 15(12), 1369-1378. [More Information]
Tattersall, M., Martin, A., Devine, R., Ryan, J., Jansen, J., Hastings, L., Boyer, M., Glare, P., Stockler, M., Butow, P. (2014). Early Contact with Palliative Care Services: A Randomized Trial in Patients with Newly Detected Incurable Metastatic Cancer. Journal of Palliative Care & Medicine, 4(1), 1-6. [More Information]
Tafreshi, A., Thientosapol, E., Liew, M., Guo, Y., Quaggiotto, M., Boyer, M., Davis, I. (2014). Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group. Asia-Pacific Journal of Clinical Oncology, 10(1), 60-65. [More Information]
Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Horvath, L., et al (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802-1809. [More Information]
Yip, P., Cooper, W., Kohonen-Corish, M., Lin, B., McCaughan, B., Boyer, M., Kench, J., Horvath, L. (2014). Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology, 67(4), 333-340. [More Information]
Boyer, M., Tsao, M., Janne, P., Ramalingam, S., Pitman Lowenthal, S., Alam, M. (2014). Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape. Asia-Pacific Journal of Clinical Oncology, 10(Suppl. 2), 2-10. [More Information]
Laurie, S., Solomon, B., Seymour, L., Ellis, P., Goss, G., Shepherd, F., Boyer, M., Arnold, A., Clingan, P., Laberge, F., Stockler, M., et al (2014). Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. European Journal of Cancer, 50(4), 706-712. [More Information]
Charakidis, M., Boyer, M. (2014). Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? Translational Lung Cancer Research, 3(6), 395-396. [More Information]
Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013). Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal Medicine Journal, 43(4), 424-429. [More Information]
van Zandwijk, N., Clarke, C., Henderson, D., Musk, A., Fong, K., Nowak, A., Loneragan, R., McCaughan, B., Boyer, M., Feigen, M., et al (2013). Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Journal of Thoracic Disease, 5(6), E254-E307. [More Information]
Honeyball, F., Boyer, M., van Zandwijk, N., Kao, S. (2013). Malignant pleural mesothelioma. Cancer Forum, 37(2), 181-185.
Spina, R., Chu, S., Chatfield, M., Chen, J., Tin, M., Boyer, M. (2013). Outcomes of Chemoradiation for Patients with Locally Advanced Non-Small-Cell Lung Cancer. Internal Medicine Journal, 43(7), 790-797. [More Information]
Coupe, N., Cox, K., Clark, K., Boyer, M., Stockler, M. (2013). Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites. Journal of Palliative Medicine, 16(8), 938-940. [More Information]
Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]
Kim, G., Mahoney, M., Szydlo, D., Mok, T., Marshke, R., Holen, K., Picus, J., Boyer, M., Pitot, H., Rubin, J., et al (2012). An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs, 30(1), 387-394. [More Information]
Sundaresan, P., Hruby, G., Hamilton, A., Hong, A., Boyer, M., Chatfield, M., Thompson, J. (2012). Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology, 24(9), e131-e136. [More Information]
Boyer, M., McCaughan, B., Barnes, D., Yip, P. (2012). Diagnosis and treatment of lung cancer: A focus on the GPs role. Medicine Today, 13(2), 30-36.
Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]
Yeo, W., Chung, H., Chan, S., Wang, L., Lim, R., Picus, J., Boyer, M., Mo, F., Koh, J., Rha, S., et al (2012). Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Journal of Clinical Oncology, 30(27), 3361-3367. [More Information]
Ramalingam, S., Blackhall, F., Krzakowski, M., Barrios, C., Park, K., Bover, I., Heo, D., Rosell, R., Talbot, D., Frank, R., Boyer, M., et al (2012). Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 30(27), 3337-3344. [More Information]
Dhillon, H., Van Der Ploeg, H., Bell, M., Boyer, M., Clarke, S., Vardy, J. (2012). The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial protocol. BMC Cancer, 12, 1-9. [More Information]
Vansteenkiste, J., Solomon, B., Boyer, M., Wolf, J., Miller, N., Di Scala, L., Pylvaenaeinen, I., Petrovic, K., Dimitrijevic, S., Anrys, B., et al (2011). Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model. Journal of Thoracic Oncology, 6(12), 2120-2129. [More Information]
Yan, T., Cao, C., Boyer, M., Tin, M., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2011). Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Annals of Thoracic and Cardiovascular Surgery, 17(3), 243-249. [More Information]
Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
Hirsh, V., Paz-Ares, L., Boyer, M., Rosell, R., Middleton, G., Eberhardt, W., Szczesna, A., Reiterer, P., Saleh, M., Arrieta, O., et al (2011). Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 29(19), 2667-2674. [More Information]
Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]
Kao, S., McCaughan, B., Muljono, A., Boyer, M. (2010). A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed. Journal of Thoracic Oncology, 5(3), 405-406. [More Information]
Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010). A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology, 66(5), 845-850. [More Information]
Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 102(16), 1253-1262. [More Information]
Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research, 16(23), 5805-5813. [More Information]
Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010). Patient-Doctor Communication: Use of Complementary and Alternative Medicine by Adult Patients with Cancer. Journal of the Society for Integrative Oncology, 8(2), 56-64. [More Information]
Pezaro, C., Rosenthal, M., Gurney, H., Davis, I., Underhill, C., Boyer, M., Kotasek, D., Soloman, B., Toner, G. (2009). An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology, 32(4), 338-341. [More Information]
Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009). Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 27(20), 3277-3283. [More Information]
Vardy, J., Dadasovich, R., Beale, P., Boyer, M., Clarke, S. (2009). Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer, 9, 1-6. [More Information]
Yan, T., Boyer, M., Tin, M., Wong, D., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009). Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. Journal of Thoracic and Cardiovascular Surgery, 138(3), 619-624. [More Information]
Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
Simonella, L., Oâ€™Connell, D., Vinod, S., Delaney, G., Boyer, M., Esmaili, N., Hensley, M., Goldsbury, D., Supramaniam, R., Hui, A., Armstrong, B. (2009). No improvement in lung cancer care: The management of lung cancer in 1996 and 2002 in New South Wales. Internal Medicine Journal, 39, 453-458. [More Information]
Yan, T., Boyer, M., Tin, M., Sim, J., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009). Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. Annals of Thoracic Surgery, 87(5), 1552-1556. [More Information]
Soon, Y., Stockler, M., Boyer, M. (2009). Reply to A.D. Sasse et al. Journal of Clinical Oncology, 27(35), e254. [More Information]
Tattersall, M., Dear, R., Jansen, J., Shepherd, H., Devine, R., Horvath, L., Boyer, M. (2009). Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre. Medical Journal of Australia, 191(4), 209-212. [More Information]
Martin, R., Fulham, M., Shannon, K., Hughes, C., Gao, K., Milross, C., Tin, M., Jackson, M., Clifford, A., Boyer, M., O'Brien, C. (2008). Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head and Neck, 31(2), 244-250. [More Information]
Vinod, S., O'Connell, D., Simonella, L., Delaney, G., Boyer, M., Peters, M., Miller, D., Peters, M., Supramaniam, R., McCawley, L., Armstrong, B. (2008). Gaps in optimal care for lung cancer. Journal of Thoracic Oncology, 3(8), 871-879. [More Information]
Kenny, P., King, M., Viney, R., Boyer, M., Pollicino, C., McLean, J., Fulham, M., McCaughan, B. (2008). Quality of life and survival in the 2 years after surgery for non-small-cell lung cancer. Journal of Clinical Oncology, 26(2), 233-241. [More Information]
Findlay, M., Storey, D., Gebski, V., Hargreaves, C., Cullingford, G., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Yuen, J., Dhillon, H., et al (2007). A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group study 9601. ANZ Journal of Surgery, 77(4), 247-252. [More Information]
Streit, J., Gao, K., O'Brien, C., Boyer, M., Milross, C. (2007). Hn11p primary chemo-radiotherapy for non-metastatic squamous cell carcinoma of the head and neck. ANZ Journal of Surgery, 77, A39.
Yeo, W., Boyer, M., Chung, H., Ong, S., Lim, R., Zee, B., Ma, B., Lam, K., Mo, F., Ng, E., Clarke, S., Beale, P., et al (2007). Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology, 59(3), 295-300. [More Information]
Chuah, B., Lim, R., Boyer, M., Ong, A., Wong, S., Kong, H., Millward, M., Clarke, S., Goh, B. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica, 46(2), 234-238. [More Information]
Oates, J., Clark, J., Jane, R., Reeves, N., Gao, K., Jackson, M., Boyer, M., O'Brien, C. (2007). Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma. Archives Of Otolaryngology-Head and Neck Surgery, 133(6), 533-540. [More Information]
Soo, R., Wang, L., Tham, L., Yong, W., Boyer, M., Lee, H., Lim, H., Millward, M., Liang, S., Beale, P., et al (2006). A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Annals of Oncology, 17(7), 1128-1133. [More Information]
Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
Hsin, K., Boyer, M., Ducreux, M., Liu, M., Soo, R., Yeo, W., Williams, K., Johri, A. (2006). Efficacy of patupilone in advanced local or metastatic gastric cancer: A phase IIa trial. Journal of Clinical Oncology, 24(18S), 195 (Abstract 4069)-195.
Abratt, R., Lee, J., Han, J., Tsai, C., Boyer, M., Mok, T., Kim, S., Lee, J., Brnabic, A., Reece, W. (2006). Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer. Journal of Thoracic Oncology, 1(2), 135-140. [More Information]
Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]
Clarke, S., Boyer, M., Millward, M., Underhill, C., Moylan, E., Yip, D., White, S., Childs, A., Beale, P., Latz, J., et al (2005). A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer, 49(3), 401-412. [More Information]
van Meerbeeck, J., Boyer, M. (2005). Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer, 49(Supplement 1), S123-S127. [More Information]
Sharma, R., Boyer, M., Clarke, S., Millward, M. (2005). Gefitinib in advanced non-small cell lung cancer. Internal Medicine Journal, 35(2), 77-82. [More Information]
Underhill, C., Hui, R., Links, M., Hawson, G., Chern, B., Yip, D., Blackwell, T., Crombie, C., Boyer, M. (2005). Phase II study of docetaxel and celecoxib as first or second line therapy in patients with advanced NSCLC. Lung Cancer, 49(Sup.2), S272-S273.
Joshua, A., Boyer, M., Subramanian, R., Clarke, S. (2005). Smoking reduction does work: resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years. Respirology, 10(2), 233-238. [More Information]
Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]
Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
Butow, P., Boyer, M., Tattersall, M., Pendlebury, S., Jackson, M., Fung, C. (2004). Cancer Consultation Preparation Package: Changing Patients But Not Physicians Is Not Enough. Journal of Clinical Oncology, 22(21), 4401-4409. [More Information]
Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049. [More Information]
Joshua, A., Stockler, M., Boyer, M. (2004). Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma. Internal Medicine Journal, 34(1-2), 70-71. [More Information]
Zhang, M., Boyer, M., Rivory, L., Hong, A., Clarke, S., Stevens, G., Fife, K. (2004). Radiosensitization Of Vinorelbine And Gemcitabine In Nci-H460 Non-Small-Cell Lung Cancer Cells. International Journal of Radiation: Oncology - Biology - Physics, 58(2), 353-360. [More Information]
Viney, R., Boyer, M., King, M., Kenny, P., Pollicino, C., McLean, J., McCaughan, B., Fulham, M. (2004). Randomized Controlled Trial Of The Role Of Positron Emission Tomography In The Management Of Stage I And Ii Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22(12), 2357-2362. [More Information]
Millward, M., Boyer, M., Lehnert, M., Clarke, S., Rischin, D., Goh, B., Wong, J., McNeil, E., Bishop, J. (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Annals of Oncology, 14(3), 449-454. [More Information]
Abol-Enein, H., Bassi, P., Boyer, M., Coppin, C., Cortesi, E., Hall, R., Horwich, A., MalmstrÃ¶m, P., Martinez-PiÃ±eiro, J., Sengelov, L., et al (2003). Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. The Lancet, 361(9373), 1927-1934. [More Information]
Vogelzang, N., Rusthoven, J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al (2003). Phase III study of premetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology, 21(14), 2636-2644. [More Information]
Boyer, M., Stockler, M., Rosenthal, M., Eisinger, D., Goad, J., Webb, D. (2002). Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2(1), 15-17. [More Information]
Boyer, M., Clarke, S. (2002). Current management of lung cancer. Current Therapeutics: Australia's journal of disease management and drug treatment, 43/44(12/1), 49-54.
Cassidy, J., Twelves, C., Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al (2002). First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology, 13, 566-575.
Boyer, M., Rivory, L., Clarke, S. (2002). Pemetrexed: single-agent and combination phase 1 study overview. Seminars in Oncology, 29(6 - Supplement 18), 18-23. [More Information]
Clarke, S., Abratt, R., Goedhals, L., Boyer, M., Millward, M., Ackland, S. (2002). Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Annals of Oncology, 13(5), 737-741. [More Information]
Horvath, L., McCaughan, B., Stockler, M., Boyer, M. (2002). Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Internal Medicine Journal, 32(3), 79-83. [More Information]
Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745. [More Information]
Rivory, L., Clarke, S., Boyer, M., Bishop, J. (2001). Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 765, 135-140.
Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.
Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.
Dowsett, S., Saul, J., Butow, P., Dunn, S., Boyer, M., Findlow, R., Dunsmore, J. (2000). Communication styles in the cancer consultation: preferences for a patient-centred approach. Psycho-Oncology, 9, 147-156.
Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.
Klasterksy, J., Paesmans, M., Rubenstein, E., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., et al (2000). The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology, 18, 3038-3051.
von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L., Clark, P., Talbot, D., Rey, A., Butler, T., Hirsh, V., et al (2000). Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Journal of Clinical Oncology, 18, 1351-1359.

show 142 more

Conferences

Findlay, M., Rankin, N., Shaw, T., White, K., Boyer, M., Milross, C., De Abreu Lourenco, R., Brown, C., Coll, J., Beale, P., et al (2018). Innovation in implementation: A new model of nutrition care for patients with head and neck cancer improves outcomes. Dietitians Association of Australia 35th National Conference, Sydney.
Miller, D., Boyer, M., Supramaniam, R., Armstrong, B., Simonella, L., O'Connell, D., Vinod, S., McCawley, L., Delaney, G. (2007). Patterns of lung cancer care in NSW, Australia. 12th World Conference on Lung Cancer, United Kingdom: Wiley-Blackwell Publishing.
Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.
Cullingford, G., Findlay, M., Storey, D., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Gebski, V., Dhillon, H. (2002). A phase II feasibility study of pre-operative and post-operative chemotherapy (epirubicin, cisplatin and 4FU (ECF)) in patients with advanced but operable gastric cancer: and Australasian Gastro-Intestinal Trials Group (AGITG) study (AG9601). 38th Annual Meeting of ASCO.

show 1 more

By Year

Expand all

2024

Brown, B., Galpin, K., Simes, R., Boyer, M., Brown, C., Chin, V., Young, J. (2024). Development of clinically meaningful quality indicators for contemporary lung cancer care, and piloting and evaluation in a retrospective cohort; experiences of the Embedding Research (and Evidence) in Cancer Healthcare (EnRICH) Program. BMJ Open, 14(2), e074399. [More Information]
Brown, L., Khou, V., Brown, C., Alexander, M., Jayamanne, D., Wei, J., Gray, L., Chan, W., Smith, S., Harden, S., Mersiades, T., Itchins, M., Pavlakis, N., Clarke, S., Boyer, M., Nagrial, A., Hau, E., Esteves Domingues Pires da Silva, I., Kao, S., Kong, B., et al (2024). First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study. Frontiers in Oncology, 14. [More Information]
Boyer, M., Hui, R., Urban, D., Clingan, P., Su, W., Devaux, C., Gadgeel, S., Garassino, M., Leopold, L., Daniel, J., et al (2024). Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer, 23(Suppl 1). [More Information]
Dowlati, A., Yoshida, T., Bouchaab, H., Borghaei, H., Felip, E., Jost, P., Gadgeel, S., Chen, X., Yu, Y., Martinez, P., Boyer, M., et al (2024). Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. Journal of Clinical Oncology, , 10.1200/JCO.24.00553. [More Information]
Smith, S., Kao, S., Boyer, M., Franco, M., Moore, M. (2024). Treatment selection and real-world analysis of immunotherapy with or without chemotherapy in PD-L1-high metastatic non-small cell lung cancer. Internal Medicine Journal. [More Information]

show 2 more

2023

Brown, B., Galpin, K., Simes, R., Boyer, M., Chin, V., Young, J. (2023). Clinicians' Evaluation of Lung Cancer Clinical Quality Indicators and Comparative Performance Data in Practice. European Journal of Cancer Care, 2023, 6636704. [More Information]
Nindra, U., Shahnam, A., Stevens, S., Pal, A., Nagrial, A., Lee, J., Yip, P., Adam, T., Boyer, M., Kao, S., et al (2023). Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia-Pacific Journal of Clinical Oncology. [More Information]

2022

Nindra, U., Shahnam, A., Stevens, S., Pal, A., Nagrial, A., Lee, J., Yip, P., Adam, T., Boyer, M., Kao, S., et al (2022). Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumab. Thoracic Cancer, 13(21), 3058-3062. [More Information]
Carroll, R., Boyer, M., Gebski, V., Hockley, B., Johnston, J., Kireta, S., Tan, H., Taylor, A., Wyburn, K., Zalcberg, J. (2022). Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study. The Lancet Oncology, 23(8), 1078-1086. [More Information]

2021

Lo, J., Ballurkar, K., Fox, S., Tynan, K., Luu, N., Boyer, M., Murali-Ganesh, R. (2021). A digital coaching intervention for cancer survivors with job loss: Retrospective study. JMIR Cancer, 7(4), e31966. [More Information]
Davis, A., Cooper, W., Boyer, M., Lee, J., Pavlakis, N., Kao, S. (2021). Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy, 13(11), 941-952. [More Information]
Davis, A., Kao, S., Clarke, S., Boyer, M., Pavlakis, N. (2021). Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opinion on Emerging Drugs, 26(2), 179-192. [More Information]
Satgunaseelan, L., Porazinski, S., Strbenac, D., Istadi, A., Willet, C., Chew, T., Sadsad, R., Palme, C., Lee, J., Boyer, M., Yang, J., Clark, J., Gupta, R., et al (2021). Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy. Frontiers in Oncology, 11, 750852. [More Information]
O Parsonson, A., Grimison, P., Boyer, M., Horvath, L., Mahon, K., Beith, J., Kao, S., Hui, M., Sutherland, S., Kumar, S., Heller, G., McNeil, C. (2021). Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemic. Journal of Telemedicine and Telecare. [More Information]
Liu, J., Itchins, M., Nagrial, A., Cooper, W., De Silva, M., Barnet, M., Varikatt, W., Sivasubramaniam, V., Davis, A., Gill, A., Blinman, P., Lee, K., Hui, R., Pavlakis, N., Clarke, S., Boyer, M., Kao, S., et al (2021). Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 155, 28-33. [More Information]

show 3 more

2020

Thomas, V., Seet-Lee, C., Marthick, M., Cheema, B., Boyer, M., Edwards, K. (2020). Aerobic exercise during chemotherapy infusion for cancer treatment: a novel randomised crossover safety and feasibility trial. Supportive Care in Cancer, 28(2), 625-632. [More Information]
Itchins, M., Lau, B., Hudson, A., Westman, H., Xia, C., Hayes, S., Howell, V., Rodriguez, M., Cooper, W., Wei, G., Buckland, M., Li, B., Gill, A., Clarke, S., Pavlakis, N., et al (2020). ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. The Oncologist, 25(8), 641-649. [More Information]
Findlay, M., Rankin, N., Shaw, T., White, K., Boyer, M., Milross, C., Lourenço, R., Brown, C., Collett, G., Beale, P., et al (2020). Best evidence to best practice: implementing an innovative model of nutrition care for patients with head and neck cancer improves outcomes. Nutrients, 12(5), 1465. [More Information]
Liu, J., Wong, K., Patanjali, N., Boyer, M., Kao, S. (2020). Case of post-progression prolongation of survival after cessation of pembrolizumab in advanced non-small-cell lung cancer. Internal Medicine Journal, 50(6), 771-773. [More Information]
Lau, B., Boyer, M., Lee, J., Kao, S. (2020). Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. Clinical Lung Cancer, 21(4), 378-3.83E+03. [More Information]
Davis, A., Boyer, M., Lee, J., Kao, S. (2020). COVID-19: the use of immunotherapy in metastatic lung cancer. Immunotherapy, 12(8), 545-548. [More Information]
Garassino, M., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., Domine, M., Hochmair, M., Powell, S., Cheng, S., Bischoff, H., Hui, R., et al (2020). Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 21(3), 387-397. [More Information]
Razak, A., Cleary, J., Moreno, V., Boyer, M., Calvo Aller, E., Edenfield, W., Tie, J., Harvey, R., Rutten, A., Shah, M., et al (2020). Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 8(2), e001006. [More Information]
Gadgeel, S., Rodriguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Domine, M., Hui, R., Hochmair, M., Clingan, P., Powell, S., et al (2020). Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38(14), 1505-1517. [More Information]

show 6 more

2019

Schuler, M., Tan, E., O’Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J., Lee, K., Lu, S., et al (2019). First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology, 145(6), 1569-1579. [More Information]
Peters, S., Dafni, U., Boyer, M., de Ruysscher, D., Faivre-Finn, C., Felip, E., Garrido, P., Girard, N., Guckenberger, M., Haanen, J., et al (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 30(2), 161-165. [More Information]
Planchard, D., Boyer, M., Lee, J., Dechaphunkul, A., Cheema, P., Takahashi, T., Gray, J., Tiseo, M., Ramalingam, S., Todd, A., et al (2019). Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 25(7), 2058-2063. [More Information]
Prasanna, T., Arasaratnam, M., Boyer, M., McNeil, C., Barnet, M., Asher, R., Hui, R., Nagrial, A., Kao, S. (2019). Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer. Immunotherapy, 11, 657-665. [More Information]
Park, K., Bennouna, J., Boyer, M., Hida, T., Hirsh, V., Kato, T., Lu, S., Mok, T., Nakagawa, K., O’Byrne, K., et al (2019). Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 132, 126-131. [More Information]

show 2 more

2018

Wu, Y., Sequist, L., Tan, E., Geater, S., Orlov, S., Zhang, L., Lee, K., Tsai, C., Kato, T., Boyer, M., et al (2018). Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer, 19(4), e465-e479. [More Information]
Ahmadzada, T., Kao, S., Reid, G., Boyer, M., Mahar, A., Cooper, W. (2018). An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 7(6), E153. [More Information]
Prasanna, T., Beith, J., Kao, S., Boyer, M., McNeil, C. (2018). Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 14(3), 125-133. [More Information]
Barnet, M., Cooper, W., Boyer, M., Kao, S. (2018). Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. Journal of Clinical Medicine, 7(6), 151. [More Information]
Findlay, M., Rankin, N., Shaw, T., White, K., Boyer, M., Milross, C., De Abreu Lourenco, R., Brown, C., Coll, J., Beale, P., et al (2018). Innovation in implementation: A new model of nutrition care for patients with head and neck cancer improves outcomes. Dietitians Association of Australia 35th National Conference, Sydney.
Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M., Powell, S., Hui, R., Boyer, M., et al (2018). Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378(22), 2078-2092. [More Information]
Gerber, D., Horn, L., Boyer, M., Sanborn, R., Natale, R., Palmero, R., Bidoli, P., Bondarenko, I., Germonpre, P., et al (2018). Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Annals of Oncology, 29(7), 1548-1553. [More Information]
Bui, K., Cooper, W., Kao, S., Boyer, M. (2018). Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 7(8), 1-18. [More Information]
Barnet, M., Blinman, P., Cooper, W., Boyer, M., Kao, S., Goodnow, C. (2018). Understanding Immune Tolerance of Cancer: Re-Purposing Insights from Fetal Allografts and Microbes. BioEssays, 40(8), 1-6. [More Information]

show 6 more

2017

Paz-Ares, L., Tan, E., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J., Mok, T., Lee, K., Lu, S., et al (2017). Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology, 28(2), 270-277. [More Information]
Barnet, M., O'Toole, S., Horvath, L., Selinger, C., Yu, B., Ng, C., Boyer, M., Cooper, W., Kao, S. (2017). EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 12(3), 585-590. [More Information]
Dhillon, H., Bell, M., van der Ploeg, H., Turner, J., Kabourakis, M., Spencer, L., Lewis, C., Hui, R., Blinman, P., Clarke, S., Boyer, M., Vardy, J. (2017). Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: A randomized controlled trial. Annals of Oncology, 28(8), 1889-1897. [More Information]
Kunchok, A., Barnes, D., Boyer, M., Halmagyi, G. (2017). Paraneoplastic cerebellar ataxia with central hypoventilation. Neurology: Neuroimmunology and Neuroinflammation, 4(1), 1-2. [More Information]
Lau, B., Kumar, S., Yan, T., Burn, J., Kennedy, C., McLean, J., Boyer, M., McCaughan, B., Kao, S. (2017). Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes. Lung Cancer, 111, 75-78. [More Information]
Roper, E., Lum, T., Palme, C., Ashford, B., Ch'ng, S., Ranson, M., Boyer, M., Clark, J., Gupta, R. (2017). PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology, 49(5), 499-505. [More Information]
van Zandwijk, N., Pavlakis, N., Kao, S., Linton, A., Boyer, M., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M., Bailey, D., Cooper, W., Kritharides, L., Reid, G., et al (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. The Lancet Oncology, 18(10), 1386-1396. [More Information]
Khoo, T., Yu, B., Smith, J., Clarke, A., Luk, P., Selinger, C., Mahon, K., Kraitsek, S., Palme, C., Boyer, M., O'Toole, S., Clark, J., Gupta, R., et al (2017). Somatic mutations in salivary duct carcinoma and potential therapeutic targets. Oncotarget, 8(44), 75893-75903. [More Information]
Kao, S., Cheng, Y., Williams, M., Kirschner, M., Madore, J., Lum, T., Sarun, K., Linton, A., McCaughan, B., Klebe, S., van Zandwijk, N., Scolyer, R., Boyer, M., Cooper, W., Reid, G. (2017). Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. [More Information]

show 6 more

2016

Park, K., Tan, E., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J., Lee, K., Lu, S., et al (2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology, 17(5), 577-589. [More Information]
Reid, G., Kao, S., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., van Zandwijk, N. (2016). Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics, 8(8), 1079-1085. [More Information]
Ramalingam, S., O'Byrne, K., Boyer, M., Mok, T., Janne, P., Zhang, H., Liang, J., Taylor, I., Sbar, E., Paz-Ares, L. (2016). Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of Oncology, 27(3), 423-429. [More Information]
Kao, S., Boyer, M. (2016). Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 34(27), 3233-3234. [More Information]
Lomax, A., Beith, J., Bhadri, V., Boyer, M., Grimison, P., Horvath, L., Kao, S., Tattersall, M., Thomas, D., McNeil, C. (2016). Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse. Internal Medicine Journal, 46(12), 1392-1398. [More Information]
Satgunaseelan, L., Gupta, R., Madore, J., Chia, N., Lum, T., Palme, C., Boyer, M., Scolyer, R., Clark, J. (2016). Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 48(6), 574-580. [More Information]
Luk, P., Weston, J., Yu, B., Selinger, C., Ekmejian, R., Eviston, T., Lum, T., Gao, K., Boyer, M., O'Toole, S., Clark, J., Gupta, R. (2016). Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head and Neck, 38(Suppl 1), e1838-e1847. [More Information]

show 4 more

2015

Davidson, A., Veillard, A., Tognela, A., Chan, M., Huighes, B., Boyer, M., Briscoe, K., Begbie, S., Abdi, E., Crombie, C., Chinchen, S., Espinoza, D., Coskinas, X., Pavlakis, N., Stockler, M., et al (2015). A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. Annals of Oncology, 26(11), 2280-2286. [More Information]
Kao, S., Fulham, M., Wong, K., Cooper, W., Brahmbhatt, H., MacDiarmid, J., Pattison, S., Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N., Clarke, S., Boyer, M., Reid, G., van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine, 191(12), 1467-1469. [More Information]
Yang, J., Wu, Y., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C., O'Byrne, K., Feng, J., Boyer, M., et al (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology, 16(2), 141-151. [More Information]
Mahon, K., Lin, H., Castillo, L., Lee, B., Lee-Ng, K., Chatfield, M., Chiam, K., Breit, S., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Horvath, L., et al (2015). Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. British Journal of Cancer, 112(8), 1340-1348. [More Information]
Brunner, M., Gore, S., Read, R., Alexander, A., Mehta, A., Elliott, M., Milross, C., Boyer, M., Clark, J. (2015). Head and neck multidisciplinary team meetings: Effect on patient management. Head and Neck, 37(7), 1046-1050. [More Information]
Cooper, W., Tran, T., Vilain, R., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P., Yu, B., O'Toole, S., McCaughan, B., Horvath, L., Kao, S., Boyer, M., Scolyer, R., et al (2015). PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2), 181-188. [More Information]

show 3 more

2014

Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
Ramalingam, S., Jänne, P., Mok, T., O'Byrne, K., Boyer, M., von Pawel, J., Pluzanski, A., Shtivelband, M., Iglesias Docampo, L., Bennouna, J., et al (2014). Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. The Lancet Oncology, 15(12), 1369-1378. [More Information]
Tattersall, M., Martin, A., Devine, R., Ryan, J., Jansen, J., Hastings, L., Boyer, M., Glare, P., Stockler, M., Butow, P. (2014). Early Contact with Palliative Care Services: A Randomized Trial in Patients with Newly Detected Incurable Metastatic Cancer. Journal of Palliative Care & Medicine, 4(1), 1-6. [More Information]
Tafreshi, A., Thientosapol, E., Liew, M., Guo, Y., Quaggiotto, M., Boyer, M., Davis, I. (2014). Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group. Asia-Pacific Journal of Clinical Oncology, 10(1), 60-65. [More Information]
Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Horvath, L., et al (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802-1809. [More Information]
Yip, P., Cooper, W., Kohonen-Corish, M., Lin, B., McCaughan, B., Boyer, M., Kench, J., Horvath, L. (2014). Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology, 67(4), 333-340. [More Information]
Boyer, M., Tsao, M., Janne, P., Ramalingam, S., Pitman Lowenthal, S., Alam, M. (2014). Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape. Asia-Pacific Journal of Clinical Oncology, 10(Suppl. 2), 2-10. [More Information]
Laurie, S., Solomon, B., Seymour, L., Ellis, P., Goss, G., Shepherd, F., Boyer, M., Arnold, A., Clingan, P., Laberge, F., Stockler, M., et al (2014). Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. European Journal of Cancer, 50(4), 706-712. [More Information]
Charakidis, M., Boyer, M. (2014). Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? Translational Lung Cancer Research, 3(6), 395-396. [More Information]

show 6 more

2013

Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013). Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal Medicine Journal, 43(4), 424-429. [More Information]
van Zandwijk, N., Clarke, C., Henderson, D., Musk, A., Fong, K., Nowak, A., Loneragan, R., McCaughan, B., Boyer, M., Feigen, M., et al (2013). Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Journal of Thoracic Disease, 5(6), E254-E307. [More Information]
Honeyball, F., Boyer, M., van Zandwijk, N., Kao, S. (2013). Malignant pleural mesothelioma. Cancer Forum, 37(2), 181-185.
Spina, R., Chu, S., Chatfield, M., Chen, J., Tin, M., Boyer, M. (2013). Outcomes of Chemoradiation for Patients with Locally Advanced Non-Small-Cell Lung Cancer. Internal Medicine Journal, 43(7), 790-797. [More Information]
Coupe, N., Cox, K., Clark, K., Boyer, M., Stockler, M. (2013). Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites. Journal of Palliative Medicine, 16(8), 938-940. [More Information]
Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]

show 5 more

2012

Kim, G., Mahoney, M., Szydlo, D., Mok, T., Marshke, R., Holen, K., Picus, J., Boyer, M., Pitot, H., Rubin, J., et al (2012). An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs, 30(1), 387-394. [More Information]
Sundaresan, P., Hruby, G., Hamilton, A., Hong, A., Boyer, M., Chatfield, M., Thompson, J. (2012). Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology, 24(9), e131-e136. [More Information]
Boyer, M., McCaughan, B., Barnes, D., Yip, P. (2012). Diagnosis and treatment of lung cancer: A focus on the GPs role. Medicine Today, 13(2), 30-36.
Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]
Yeo, W., Chung, H., Chan, S., Wang, L., Lim, R., Picus, J., Boyer, M., Mo, F., Koh, J., Rha, S., et al (2012). Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Journal of Clinical Oncology, 30(27), 3361-3367. [More Information]
Ramalingam, S., Blackhall, F., Krzakowski, M., Barrios, C., Park, K., Bover, I., Heo, D., Rosell, R., Talbot, D., Frank, R., Boyer, M., et al (2012). Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 30(27), 3337-3344. [More Information]
Dhillon, H., Van Der Ploeg, H., Bell, M., Boyer, M., Clarke, S., Vardy, J. (2012). The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial protocol. BMC Cancer, 12, 1-9. [More Information]

show 4 more

2011

Vansteenkiste, J., Solomon, B., Boyer, M., Wolf, J., Miller, N., Di Scala, L., Pylvaenaeinen, I., Petrovic, K., Dimitrijevic, S., Anrys, B., et al (2011). Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model. Journal of Thoracic Oncology, 6(12), 2120-2129. [More Information]
Yan, T., Cao, C., Boyer, M., Tin, M., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2011). Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Annals of Thoracic and Cardiovascular Surgery, 17(3), 243-249. [More Information]
Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
Hirsh, V., Paz-Ares, L., Boyer, M., Rosell, R., Middleton, G., Eberhardt, W., Szczesna, A., Reiterer, P., Saleh, M., Arrieta, O., et al (2011). Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 29(19), 2667-2674. [More Information]
Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]

show 2 more

2010

Kao, S., McCaughan, B., Muljono, A., Boyer, M. (2010). A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed. Journal of Thoracic Oncology, 5(3), 405-406. [More Information]
Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010). A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology, 66(5), 845-850. [More Information]
Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 102(16), 1253-1262. [More Information]
Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research, 16(23), 5805-5813. [More Information]
Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010). Patient-Doctor Communication: Use of Complementary and Alternative Medicine by Adult Patients with Cancer. Journal of the Society for Integrative Oncology, 8(2), 56-64. [More Information]

show 2 more

2009

Pezaro, C., Rosenthal, M., Gurney, H., Davis, I., Underhill, C., Boyer, M., Kotasek, D., Soloman, B., Toner, G. (2009). An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology, 32(4), 338-341. [More Information]
Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009). Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 27(20), 3277-3283. [More Information]
Vardy, J., Dadasovich, R., Beale, P., Boyer, M., Clarke, S. (2009). Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer, 9, 1-6. [More Information]
Yan, T., Boyer, M., Tin, M., Wong, D., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009). Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. Journal of Thoracic and Cardiovascular Surgery, 138(3), 619-624. [More Information]
Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
Simonella, L., Oâ€™Connell, D., Vinod, S., Delaney, G., Boyer, M., Esmaili, N., Hensley, M., Goldsbury, D., Supramaniam, R., Hui, A., Armstrong, B. (2009). No improvement in lung cancer care: The management of lung cancer in 1996 and 2002 in New South Wales. Internal Medicine Journal, 39, 453-458. [More Information]
Yan, T., Boyer, M., Tin, M., Sim, J., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009). Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. Annals of Thoracic Surgery, 87(5), 1552-1556. [More Information]
Soon, Y., Stockler, M., Boyer, M. (2009). Reply to A.D. Sasse et al. Journal of Clinical Oncology, 27(35), e254. [More Information]
Tattersall, M., Dear, R., Jansen, J., Shepherd, H., Devine, R., Horvath, L., Boyer, M. (2009). Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre. Medical Journal of Australia, 191(4), 209-212. [More Information]

show 6 more

2008

Martin, R., Fulham, M., Shannon, K., Hughes, C., Gao, K., Milross, C., Tin, M., Jackson, M., Clifford, A., Boyer, M., O'Brien, C. (2008). Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head and Neck, 31(2), 244-250. [More Information]
Vinod, S., O'Connell, D., Simonella, L., Delaney, G., Boyer, M., Peters, M., Miller, D., Peters, M., Supramaniam, R., McCawley, L., Armstrong, B. (2008). Gaps in optimal care for lung cancer. Journal of Thoracic Oncology, 3(8), 871-879. [More Information]
Kenny, P., King, M., Viney, R., Boyer, M., Pollicino, C., McLean, J., Fulham, M., McCaughan, B. (2008). Quality of life and survival in the 2 years after surgery for non-small-cell lung cancer. Journal of Clinical Oncology, 26(2), 233-241. [More Information]

2007

Findlay, M., Storey, D., Gebski, V., Hargreaves, C., Cullingford, G., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Yuen, J., Dhillon, H., et al (2007). A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group study 9601. ANZ Journal of Surgery, 77(4), 247-252. [More Information]
Streit, J., Gao, K., O'Brien, C., Boyer, M., Milross, C. (2007). Hn11p primary chemo-radiotherapy for non-metastatic squamous cell carcinoma of the head and neck. ANZ Journal of Surgery, 77, A39.
Yeo, W., Boyer, M., Chung, H., Ong, S., Lim, R., Zee, B., Ma, B., Lam, K., Mo, F., Ng, E., Clarke, S., Beale, P., et al (2007). Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology, 59(3), 295-300. [More Information]
Chuah, B., Lim, R., Boyer, M., Ong, A., Wong, S., Kong, H., Millward, M., Clarke, S., Goh, B. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica, 46(2), 234-238. [More Information]
Miller, D., Boyer, M., Supramaniam, R., Armstrong, B., Simonella, L., O'Connell, D., Vinod, S., McCawley, L., Delaney, G. (2007). Patterns of lung cancer care in NSW, Australia. 12th World Conference on Lung Cancer, United Kingdom: Wiley-Blackwell Publishing.
Oates, J., Clark, J., Jane, R., Reeves, N., Gao, K., Jackson, M., Boyer, M., O'Brien, C. (2007). Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma. Archives Of Otolaryngology-Head and Neck Surgery, 133(6), 533-540. [More Information]

show 3 more

2006

Soo, R., Wang, L., Tham, L., Yong, W., Boyer, M., Lee, H., Lim, H., Millward, M., Liang, S., Beale, P., et al (2006). A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Annals of Oncology, 17(7), 1128-1133. [More Information]
Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]
Hsin, K., Boyer, M., Ducreux, M., Liu, M., Soo, R., Yeo, W., Williams, K., Johri, A. (2006). Efficacy of patupilone in advanced local or metastatic gastric cancer: A phase IIa trial. Journal of Clinical Oncology, 24(18S), 195 (Abstract 4069)-195.
Abratt, R., Lee, J., Han, J., Tsai, C., Boyer, M., Mok, T., Kim, S., Lee, J., Brnabic, A., Reece, W. (2006). Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer. Journal of Thoracic Oncology, 1(2), 135-140. [More Information]
Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]

show 3 more

2005

Clarke, S., Boyer, M., Millward, M., Underhill, C., Moylan, E., Yip, D., White, S., Childs, A., Beale, P., Latz, J., et al (2005). A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer, 49(3), 401-412. [More Information]
van Meerbeeck, J., Boyer, M. (2005). Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer, 49(Supplement 1), S123-S127. [More Information]
Sharma, R., Boyer, M., Clarke, S., Millward, M. (2005). Gefitinib in advanced non-small cell lung cancer. Internal Medicine Journal, 35(2), 77-82. [More Information]
Underhill, C., Hui, R., Links, M., Hawson, G., Chern, B., Yip, D., Blackwell, T., Crombie, C., Boyer, M. (2005). Phase II study of docetaxel and celecoxib as first or second line therapy in patients with advanced NSCLC. Lung Cancer, 49(Sup.2), S272-S273.
Joshua, A., Boyer, M., Subramanian, R., Clarke, S. (2005). Smoking reduction does work: resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years. Respirology, 10(2), 233-238. [More Information]
Clarke, S., Boyer, M., Stockler, M., Venkatawaran, R., Nordman, I., Joshua, A. (2005). Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting, NY, USA: American Society of Clinical Oncology.
Joshua, A., Nordman, I., Venkataswaran, R., Clarke, S., Stockler, M., Boyer, M. (2005). Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal, 35(8), 468-472. [More Information]

show 4 more

2004

Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
Butow, P., Boyer, M., Tattersall, M., Pendlebury, S., Jackson, M., Fung, C. (2004). Cancer Consultation Preparation Package: Changing Patients But Not Physicians Is Not Enough. Journal of Clinical Oncology, 22(21), 4401-4409. [More Information]
Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049. [More Information]
Joshua, A., Stockler, M., Boyer, M. (2004). Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma. Internal Medicine Journal, 34(1-2), 70-71. [More Information]
Zhang, M., Boyer, M., Rivory, L., Hong, A., Clarke, S., Stevens, G., Fife, K. (2004). Radiosensitization Of Vinorelbine And Gemcitabine In Nci-H460 Non-Small-Cell Lung Cancer Cells. International Journal of Radiation: Oncology - Biology - Physics, 58(2), 353-360. [More Information]
Viney, R., Boyer, M., King, M., Kenny, P., Pollicino, C., McLean, J., McCaughan, B., Fulham, M. (2004). Randomized Controlled Trial Of The Role Of Positron Emission Tomography In The Management Of Stage I And Ii Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22(12), 2357-2362. [More Information]

show 3 more

2003

Millward, M., Boyer, M., Lehnert, M., Clarke, S., Rischin, D., Goh, B., Wong, J., McNeil, E., Bishop, J. (2003). Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Annals of Oncology, 14(3), 449-454. [More Information]
Abol-Enein, H., Bassi, P., Boyer, M., Coppin, C., Cortesi, E., Hall, R., Horwich, A., MalmstrÃ¶m, P., Martinez-PiÃ±eiro, J., Sengelov, L., et al (2003). Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. The Lancet, 361(9373), 1927-1934. [More Information]
Vogelzang, N., Rusthoven, J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al (2003). Phase III study of premetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology, 21(14), 2636-2644. [More Information]
Boyer, M. (2003). Pleural and pericardial effusions. In Fisch, Bruera (Eds.), Handbook of Advanced Cancer Care, (pp. 481-487). UK: Cambridge University Press.

show 1 more

2002

Cullingford, G., Findlay, M., Storey, D., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Gebski, V., Dhillon, H. (2002). A phase II feasibility study of pre-operative and post-operative chemotherapy (epirubicin, cisplatin and 4FU (ECF)) in patients with advanced but operable gastric cancer: and Australasian Gastro-Intestinal Trials Group (AGITG) study (AG9601). 38th Annual Meeting of ASCO.
Boyer, M., Stockler, M., Rosenthal, M., Eisinger, D., Goad, J., Webb, D. (2002). Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2(1), 15-17. [More Information]
Boyer, M., Clarke, S. (2002). Current management of lung cancer. Current Therapeutics: Australia's journal of disease management and drug treatment, 43/44(12/1), 49-54.
Cassidy, J., Twelves, C., Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al (2002). First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology, 13, 566-575.
Boyer, M., Rivory, L., Clarke, S. (2002). Pemetrexed: single-agent and combination phase 1 study overview. Seminars in Oncology, 29(6 - Supplement 18), 18-23. [More Information]
Clarke, S., Abratt, R., Goedhals, L., Boyer, M., Millward, M., Ackland, S. (2002). Phase II trial of pemetrexed disodium (ALIMTA[R], LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Annals of Oncology, 13(5), 737-741. [More Information]
Horvath, L., McCaughan, B., Stockler, M., Boyer, M. (2002). Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Internal Medicine Journal, 32(3), 79-83. [More Information]

show 4 more

2001

Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745. [More Information]
Rivory, L., Clarke, S., Boyer, M., Bishop, J. (2001). Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 765, 135-140.

2000

Rischin, D., Boyer, M., Smith, J., Millward, M., Michael, M., Bishop, J., Zalcberg, J., Davison, J., Emmett, E., McClure, B. (2000). A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 11, 421-426.
Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.
Dowsett, S., Saul, J., Butow, P., Dunn, S., Boyer, M., Findlow, R., Dunsmore, J. (2000). Communication styles in the cancer consultation: preferences for a patient-centred approach. Psycho-Oncology, 9, 147-156.
Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.
Klasterksy, J., Paesmans, M., Rubenstein, E., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., et al (2000). The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology, 18, 3038-3051.
von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L., Clark, P., Talbot, D., Rey, A., Butler, T., Hirsh, V., et al (2000). Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Journal of Clinical Oncology, 18, 1351-1359.

show 3 more

Selected Grants

2023

The Centre of Research Excellence for Applied Innovations in Oral Cancer, Clark J, Crook J, Li Q, Gupta R, Boyer M, Yang J, Palendira M, National Health and Medical Research Council (NHMRC)/Centres of Research Excellence

2021

Personalised Immunotherapy Program - Precision immunotherapies for multiple solid tumours using a biomarker driven adaptive enrichment clinical trials platform, Wilmott J, Long G, Scolyer R, Boyer M, Lo S, Menzies A, Morton R, Esteves Domingues Pires da Silva I, Cooper W, Cust A, Gide T, Cancer Institute NSW/Translational Program Grant
Reducing the Morbidity of Head and Neck Cancer Treatment, Clark J, Yang J, Suaning G, Gupta R, Boyer M, Altmann E, Cancer Institute NSW/Translational Program Grant

2016

Sydney Catalyst - the Translational Cancer Research Centre of central Sydney and regional NSW, Boyer M, Simes R, Hogg P, Butow P, Thomas D, Young J, Vadas M, Cancer Institute NSW/Translational Cancer Research Centre

2013

NITRO Trial: A randomised phase III trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer, Davidson A, Boyer M, Millward M, Mitchell P, McLachlan S, Hughes B, National Health and Medical Research Council (NHMRC)/Project Grants

2012

QX100 Droplet Digital PCR system for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility, Ammit A, Bagley E, Bao B, Boyer M, Byrne M, Camp A, Day M, Dong Q, Dos Remedios C, Fraser S, Fu D, Hanrahan J, Hibbs D, Huang M, Jansson P, Ju Y, Kovacevic Z, Kril J, Lai D, Lane D, Lay P, Lyons J, Morris B, Murphy C, Rendina L, Richardson D, Sutherland G, Vandenberg R, Whittington R, Zhang D, Scolyer R, Black J, Halliday G, Christie M, Zreiqat H, Murray M, Slobedman B, Naylor M, Burgess J, Triccas J, Mason R, Chadban S, Combes V, Lovicu F, McLennan S, Kalinowski D, Sharland A, Johnstone D, Groundwater P, Dixon K, Zhou F, Lovejoy D, Lu Z, Zhu L, Goldsbury C, Witting P, Buckland M, Assinder S, Purdie (Williams) A, Codd R, Owens T, Hambly B, National Health and Medical Research Council (NHMRC)/Equipment Grant
Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility, Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons J, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho P, Williamson P, Murphy C, DVC Research/Equipment Grant
Development and operational support for the Australasian Lung Cancer Trials Group (ALTG) through the NHMRC Clinical Trial Centre: A NSW-led initiative, Pavlakis N, Boyer M, Stockler M, Dhillon H, Links M, Brown C, Lewis C, Stubbin I, Cancer Institute NSW/Cooperative Clinical Trial (CCT) Grants

2011

GeneAtlas Personal Microarray System, Richardson D, Scolyer R, Stocker R, Weninger W, Black J, Allen D, Murray M, Mason R, Twigg S, King N, Horvath L, Lovicu F, Lee C, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufogalis B, Hambly B, Morris B, Bao B, Bishop A, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina L, Byrne M, Naylor M, Cole N, Jansson P, Dong Q, Codd R, Payne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto A, Lai D, Yu Y, Ju Y, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes R, Zhang D, Boyer M, Murphy C, National Health and Medical Research Council (NHMRC)/Equipment Grant

2010

NITRO: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer, Davidson A, Millward M, Boyer M, Millward M, Fong K, McLachlan S, Singhal N, Stockler M, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
GenomeLab GeXP Genetic Analysis System for the Multi-Disciplinary Sydney Cancer Gene Expression Facility, Richardson D, Halliday G, Scolyer R, Clarke S, Lee C, Reichardt J, Clarke C, Murray M, Boyer M, Kefford R, Cancer Institute NSW/Equipment Grant

2008

Preferences for adjuvant chemotherapy in early non-small-cell lung cancer: What makes it worthwhile to patients and their doctors, McLachlan S, Duric V, Stockler M, Nowak A, Wright G, Boyer M, Hudson H, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme

2007

A randomised, phase III trial of adding nitroglycerin to first line chemotherapy in advanced non-small cell lung cancer, Davidson A, Boyer M, Stockler M, Cancer Council NSW/Research Project Grants

2006

Pre-clinical development of DpT iron chelators for cancer treatment, Boyer M, Horvath L, Lovejoy D, Richardson D, Cancer Institute NSW/Research Grant

2005

The effects of chemotherapy on cognitive function in patients with testicular cancer, Boyer M, Cancer Council NSW/Research Project Grants

1999

RCT:economic evaluation of positron emission tomography in management of non small cell lung cancer, Viney R, Boyer M, Fulham M, King M, National Health and Medical Research Council (NHMRC)/Project Grants
Preparing cancer patients for clinical decision making: a randomised trial of preconsultation preparation packages, Boyer M, Butow P, Tattersall M, National Health and Medical Research Council (NHMRC)/Project Grants

Faculty of Medicine and Health

Page not found

Professor Michael Boyer

Publications

By Type

By Year

Selected Grants

2023

2021

2016

2013

2012

2011

2010

2008

2007

2006

2005

1999